静脉环磷酰胺脉冲治疗对早期系统性硬化症皮肤纤维化的疗效
该回顾性队列纳入143例系统性硬化症(SSc)患者,均接受至少6次静脉环磷酰胺(CYC)脉冲治疗(750 mg/m2/月),以mRSS评估皮肤增厚。43%的弥漫性皮肤型SSc(dcSSc)患者在12个月时达到临床相关应答,第6个月无应答可预测第12个月无应答(OR 37.1;95%CI 4.5, 306.4)。
要点
- 静脉CYC脉冲治疗可使43%的dcSSc患者在第12个月达到mRSS下降≥5分且≥25%的临床相关应答。
- 第6个月无应答者中仅29%在第12个月出现应答,第6个月无应答可强烈预测第12个月无应答。
- 静脉CYC脉冲治疗可考虑作为dcSSc患者皮肤增厚的有效治疗选择。
核心结论
- 静脉CYC脉冲治疗应被视为dcSSc患者皮肤增厚的有效治疗选择,因43%的dcSSc患者达到临床相关应答。
- 第6个月无应答的dcSSc患者中仅29%在第12个月出现应答,此发现有助于医患共同决策是否继续治疗。
研究设计与样本
- 回顾性评估143例SSc患者从基线至12、24、36个月的数据。
- 所有患者接受至少6次静脉CYC脉冲治疗(750 mg/m2/月)。
- 采用改良Rodnan皮肤评分(mRSS)评估皮肤增厚,临床相关应答定义为mRSS较基线下降5分且25%。
- 采用logistic回归分析检验不同基线变量对第12个月应答的预测作用。
主要发现
- 43%(n=42)的dcSSc患者在第12个月达到临床相关应答。
- 第6个月无应答可预测第12个月无应答(比值比37.1;95%CI 4.5, 306.4)。
- 第6个月无应答的dcSSc患者中仅29%在第12个月出现应答。
关键数值与推荐
- 临床相关应答定义为mRSS较基线下降5分且25%。
- 静脉CYC脉冲治疗方案为750 mg/m2/月,至少6次。
- 第6个月无应答预测第12个月无应答的比值比为37.1(95%CI 4.5, 306.4)。
临床怎么用
- 静脉CYC脉冲治疗可用于dcSSc患者皮肤增厚的治疗。
- 治疗第6个月评估应答情况,无应答者继续治疗至第12个月出现应答的可能性较低,可据此与患者共同决策是否继续治疗。
局限性
- 本研究为回顾性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: SSc is a autoimmune disease characterized by fibrosis of the skin and internal organs. There is a lack of evidence for the efficacy of i.v. CYC pulse therapy on skin thickening. We aimed to examine the response of i.v. CYC pulse therapy on skin thickening in our cohort of SSc patients and analysed factors that predict this response. METHODS: We retrospectively evaluated the data for 143 patients with SSc from baseline to 12, 24 and 36 months. All patients were treated with at least 6 i.v. CYC pulses (750 mg/m2/month). We applied the modified Rodnan Skin Score (mRSS) to assess skin thickening. A clinically relevant response was defined as a decrease in mRSS of 5 points and 25% from baseline. Different baseline variables for predicting response on month 12 were tested in logistic regression analyses. RESULTS: Baseline characteristics of the patients with dcSSc and lcSSc were collected. Forty-three percent (n = 42) of dcSSc patients had a clinically relevant response on month 12. Non-responding on month 6 predicts non-response on month 12 (odds ratio 37.1; 95% CI 4.5, 306.4). CONCLUSION: We concluded that i.v. CYC pulse therapy should be considered as an effective treatment option for skin thickening in dcSSc patients, because 43% of this group of patients were found to have a clinically relevant response. Of the dcSSC patients who did not respond by month 6, only 29% had a response by month 12. This finding can help the physician and patient in shared decision making about whether or not to continue therapy.
引用
- Kersten BE, den Broeder N, van den Hoogen FHJ, et al. Treatment with cyclophosphamide i.v. pulse therapy is an option for effective treatment of skin fibrosis in patients with early systemic sclerosis. Rheumatology (Oxford). 2020. PMID: 31628802. doi:10.1093/rheumatology/kez487
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。